Vis enkel innførsel

dc.contributor.authorAllaoui, Giovanni
dc.contributor.authorRylander, Karin Charlotta Maria
dc.contributor.authorFuskevåg, Ole Martin
dc.contributor.authorGrimnes, Guri
dc.contributor.authorAverina, Maria
dc.contributor.authorWilsgaard, Tom
dc.contributor.authorBerg, Vivian Hætta
dc.date.accessioned2024-10-07T07:29:49Z
dc.date.available2024-10-07T07:29:49Z
dc.date.issued2024-03-18
dc.description.abstractAim We aimed to investigate changes in pre-diagnostic concentrations of classic and 11-oxygenated androgens in type 2 diabetes (T2DM) cases and healthy controls, associations between androgen concentrations and T2DM, and the potential for androgens to improve the prediction of T2DM when considered in combination with established risk factors.<p> <p>Methods Androgen concentrations were analysed in serum samples from 116 T2DM cases and 138 controls at 3, pre-diagnostic time-points: 1986/87 (T1), 1994/95 (T2), and 2001 (T3). Generalised estimating equations were used to longitudinally examine androgen concentrations, and logistic regression models were used to estimate the odds ratios (OR) of T2DM at each time-point. Logistic regression models were also used to calculate area under the receiver operating characteristics curve (AROC) from models including established risk factors alone (ERF model) and established risk factors plus each androgen, respectively, which were compared to identify improvements in predictive ability. <p>Results For women, no significant associations were observed between any of the investigated androgens and T2DM after adjusting for confounders. For men, after adjusting for confounders, concentrations of all investigated 11-oxygenated androgens were higher in cases than controls at one or several time-points. We observed associations between T2DM and concentrations of 11-ketoandrostenedione (OR: 1.59) and 11-ketotestosterone (OR: 1.62) at T1; and 11-hydroxyandrostenedione (OR: 2.00), 11-hydroxytestosterone (OR: 1.76), 11-ketoandrostenedione (OR: 1.84), 11-ketotestosterone (OR: 1.78) and testosterone (OR: 0.45) at T3 in men. The addition of these androgens (including 11-hydroxytestosterone at T2) to the ERF model resulted in an improved ability to predict T2DM in men (AROC: 0.79–0.82). We did not observe significant differences in changes in androgen concentrations over time between cases and controls in either sex. <p>Conclusion Our results demonstrate that testosterone and 11-oxygenated androgens are associated with T2DM in men before diagnosis and may be potential biomarkers in T2DM risk assessment.en_US
dc.identifier.citationAllaoui, Rylander, Fuskevåg, Grimnes, Averina, Wilsgaard, Berg. Longitudinal assessment of classic and 11-oxygenated androgen concentrations and their association with type 2 diabetes mellitus development: the Tromsø study. Acta Diabetologica. 2024en_US
dc.identifier.cristinIDFRIDAID 2262823
dc.identifier.doi10.1007/s00592-024-02266-5
dc.identifier.issn0940-5429
dc.identifier.issn1432-5233
dc.identifier.urihttps://hdl.handle.net/10037/35064
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.relation.journalActa Diabetologica
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleLongitudinal assessment of classic and 11-oxygenated androgen concentrations and their association with type 2 diabetes mellitus development: the Tromsø studyen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution 4.0 International (CC BY 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution 4.0 International (CC BY 4.0)